Goserelin-Linked Trial NCT03701334 Update: Phase 3 Status Active, Not Recruiting

On September 18, 2026, a status update was recorded for a clinical trial involving goserelin as part of endocrine therapy. The trial, registered as NCT03701334, is titled "A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer." It is a Phase 3 study. Its current status is listed as active, not recruiting. This designation means the trial is ongoing but is no longer enrolling new participants. No results have been posted as part of this update. The trial evaluates ribociclib in combination with endocrine therapy, a category that can include goserelin, as an adjuvant treatment approach in patients with hormone receptor positive, HER2 negative early breast cancer. Further details on trial design, enrollment criteria, and outcomes measures can be found in the official registry listing. This brief reflects only the status update as recorded and does not describe efficacy or safety outcomes. Readers interested in the broader context of goserelin as an approved compound can consult the compound overview for additional background.